T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Association between inflammatory and obesity markers in a Swiss population-based sample (CoLaus Study).
Pedro Marques-Vidal,Murielle Bochud,François Bastardot,Thomas F. Lüscher,François Ferrero,Jean-Michel Gaspoz,Fred Paccaud,Adrian Urwyler,Roland von Känel,Christoph Hock,Gérard Waeber,Martin Preisig,Peter Vollenweider +12 more
TL;DR: Obesity markers are differentially associated with cytokine levels, and BMI, waist circumference and waist circumference are associated with TNF-α; all obesity markers are positively associated with hs-CRP.
Journal ArticleDOI
Histamine H1 Receptor Promotes Atherosclerotic Lesion Formation by Increasing Vascular Permeability for Low-Density Lipoproteins
Izabela Rozenberg,Susanna H. M. Sluka,Lucia Rohrer,Janin Hofmann,Burkhard Becher,Alexander Akhmedov,Jorge Soliz,Pavani Mocharla,Jan Borén,Pål Johansen,Jan Steffel,Takeshi Watanabe,Thomas F. Lüscher,Felix C. Tanner +13 more
TL;DR: It is indicated that H1 but not H2 receptor activation drives the formation of atherosclerotic lesions through an increased vascular permeability for LDL, which is associated with an enhanced secondary aortic and systemic inflammation.
Journal ArticleDOI
Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?
TL;DR: The therapeutic potential of ET antagonists as antiarrhythmic drugs and proposed mechanisms for the arrhythmogenic effects of ET-1 are prolongation or increased dispersion of monophasic action potential duration, QT prolongation, development of early afterdepolarizations, acidosis, and augmentation of cellular injury.
Journal ArticleDOI
Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction
Alfredo R. Galassi,Marouane Boukhris,Aurel Toma,Zied Ibn Elhadj,Lobna Laroussi,Oliver Gaemperli,Michael Behnes,Ibrahim Akin,Thomas F. Lüscher,Franz J. Neumann,Kambis Mashayekhi +10 more
TL;DR: In CTO patients with low LVEf, PCI could represent a safe and effective revascularization strategy achieving good midterm outcome and LVEF improvement.
Journal ArticleDOI
Levels and determinants of inflammatory biomarkers in a Swiss population-based sample (CoLaus study).
Pedro Marques-Vidal,Murielle Bochud,François Bastardot,Thomas F. Lüscher,François Ferrero,Jean-Michel Gaspoz,Fred Paccaud,Adrian Urwyler,Roland von Känel,Christoph Hock,Gérard Waeber,Martin Preisig,Peter Vollenweider +12 more
TL;DR: In this article, the levels and determinants of interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α and C-reactive protein (CRP) were assessed by a multiplexed particle-based flow cytometric assay and CRP by an immunometric assay.